MHRA raps Lloydspharmacy for sildenafil promotion
Practice The MHRA has upheld a complaint from a member of the public who was sent an email promoting a prescription-only erectile dysfunction drug
The MHRA has rapped Lloydspharmacy for promoting a prescription-only drug for erectile dysfunction by email.
The medicines watchdog upheld a complaint made by a member of the public last June about the promotion of sildenafil, it announced last week (September 13).
Lloydspharmacy admitted it had unintentionally sent an email about sildenafil pricing to customers who had previously ordered "various medicines" for erectile dysfunction.
Lloydspharmacy admitted it had unintentionally sent an email about sildenafil pricing to customers who had not previously received the drug |
More on pharmacy PR Pharmacy must rebuild its image after PR crisis, C+D readers warn GPhC extends pharmacist's suspension for web advertising breach |
The multiple told the MHRA that it would ensure it only sent product price announcements to customers who had previously received that particular medicine in future. |
Advertisements that are likely to lead to the use of a prescription-only medicine are prohibited under the human medicines regulations.
Any information that is given must be "factual and balanced", and avoid encouraging patients to request the medicine, says the Association of the British Pharmaceutical Industry code of practice.
Lloydspharmacy told C+D it had nothing to add to the MHRA's announcement.
What measures do you have in place to prevent this kind of promotion? Comment below or email us at [email protected] You can also find C+D on Twitter, LinkedIn and Facebook |